Enveda Advances AI-Discovered, Nature-Derived Drug ENV-294 to Phase 1 Trials
Enveda, a biotechnology company transforming nature’s chemistry into medicines using AI, has announced the FDA clearance of an investigational new drug (IND) application for ENV-294. This first-in-class small molecule, designed to treat atopic dermatitis (eczema) and other inflammatory conditions, has now entered Phase 1 clinical trials, with the first patient dosed in late October.
Enveda’s platform combines advanced AI models, including PRISM, the first foundation model designed for natural chemistry, and the world’s largest searchable natural product library. PRISM is trained on over a billion small molecule mass spectra, allowing Enveda to identify and characterize molecules 10,000 times faster than traditional methods. ENV-294 is the first drug to reach clinical trials from this platform.
Viswa Colluru, Ph.D., CEO and Founder at Enveda
“I witnessed the profound impact a new therapeutic can have on a patient, and their family, during my mom's battle with cancer, and I founded Enveda to provide that life-saving power—and hope—to as many people as possible with whatever condition they may be dealing with. Today’s achievement underscores the progress we’ve made in such a short time, creating tremendous opportunity not just for Enveda but for doctors and patients around the world.”
Enveda's platform is designed with a multidimensional approach:
- Organize: The world’s largest searchable library of natural products, indexing 38,000 plants linked to 12,000 human diseases.
- Translate: PRISM, a foundation model for natural chemistry, decodes molecular structures and properties.
- Apply: A fully automated lab that screens molecules for therapeutic potential.
With ENV-294, Enveda aims to address the unmet need for safe and effective oral treatments for eczema, a condition affecting over 30 million people in the U.S. The drug offers a potential alternative to injectable treatments and oral therapies with significant toxicities.
Jonathan Silverberg, MD, Ph.D., MPH, George Washington University
“Atopic dermatitis is a highly burdensome disease. Despite great progress over the last decade with respect to novel treatments, there remain multiple unmet needs for safe and effective oral treatments to treat patients with moderate to severe AD. Enveda’s novel approach using a naturally derived drug molecule holds great promise for the treatment of AD.”
Cover photo: River of Yosemite Valley, California, by zodebala
Topics: Clinical Trials
